News

AstraZeneca completes $2 billion investment in Summit Therapeutics

The companies are advancing ivonescimab in combination with antibody-drug conjugates (ADCs) across multiple tumour types

  • By IPP Bureau | October 06, 2026
AstraZeneca has completed its $2 billion equity investment in Summit Therapeutics, a move aimed at accelerating development of ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF.
 
The companies are advancing ivonescimab in combination with antibody-drug conjugates (ADCs) across multiple tumour types, expanding the potential scope of the cancer treatment.
 
Under a previously announced clinical collaboration, AstraZeneca and Summit will also evaluate sonesitatug vedotin (Sone-Ve) in combination with ivonescimab. The companies plan to enter into a further agreement to launch a global development programme combining ivonescimab with other AstraZeneca cancer medicines, including additional ADCs.
 
The push comes as AstraZeneca, Daiichi Sankyo and Summit broaden their collaboration. In a separate agreement, AstraZeneca and Daiichi Sankyo agreed to a clinical collaboration with Summit to evaluate Datroway (datopotamab deruxtecan) alongside ivonescimab across multiple tumour types, including lung and breast cancers.

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.